

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/849,696	05/20/2004	Charles A. Francis	060525-5006-00	7625
28977 75	590 11/17/2004		EXAM	INER
MORGAN, LEWIS & BOCKIUS LLP			AULAKH, CHARANJIT	
1701 MARKET STREET PHILADELPHIA, PA 19103-2921			ART UNIT	PAPER NUMBER
			1625	
			DATE MAILED: 11/17/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/849,696	FRANCIS, CHARLES A.				
Office Action Summary	Examiner	Art Unit				
	Charanjit S. Aulakh	1625				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wi	th the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory perions - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a re- reply within the statutory minimum of thirt od will apply and will expire SIX (6) MON tute, cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).				
Status		:				
1) Responsive to communication(s) filed on	·	,				
<u> </u>	his action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) ☐ Claim(s) 1-30 is/are pending in the application 4a) Of the above claim(s) is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-30 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers						
9)☐ The specification is objected to by the Exami	ner.					
10)☐ The drawing(s) filed on is/are: a)☐ a	ccepted or b) objected to t	by the Examiner.				
Applicant may not request that any objection to the		· ,				
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a list	ents have been received. ents have been received in Apriority documents have been eau (PCT Rule 17.2(a)).	pplication No received in this National Stage				
Attachment(s)						
) Notice of References Cited (PTO-892)	4) Interview S	ummary (PTO-413)				
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0-Paper No(s)/Mail Date 2. 	Paper No(s))/Mail Date formal Patent Application (PTO-152)				

Art Unit: 1625

DETAILED ACTION

1. Claims 1-30 are pending in the application.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 5 recites the limitation "single solvent system" in claim 1. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 4. Claims 1-14 are rejected under 35 U.S.C. 102(b) as being anticipated by Ayyanagar (U.S. Patent no. 4,764,615, cited on applicants form 1449).

Ayyanagar discloses a process for the preparation of codeine from morphine. The process disclosed by Ayyanagar (see claims as well as examples 1-6) anticipates the instant claims when alkaline ingredient is alkali metal carbonate or potassium carbonate.

5. Claims 1-8 and 11-14 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Phillips (Chemist Druggist, cited on applicants form 1449).

Phillips discloses a process for preparing codeine by methylation of morphine in an alkaline solution and therefore, clearly anticipate the instant claims.

Application/Control Number: 10/849,696

Art Unit: 1625

Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. Claims 15-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ayyanagar (U.S. Patent no. 4,764,615, cited on applicants form 1449).

Ayyanagar discloses a process for the preparation of codeine from morphine.

Ayyanagar meets all the limitations except that it uses alkali metal carbonate instead of alkali metal phosphate (see examples 1-6). However, potassium carbonate as well as the instant alkali metal phosphates are all alkaline ingredients and therefore, in absence of an unexpected results of superior yield with the instant alkali metal phosphates over alkaline ingredient, potassium carbonate disclosed by Ayyanagar, it would have been obvious to one skilled in the art to use other alkaline ingredients in the process of Ayyanagar since the yield and purity of codeine is obtained up to 99% by using alkaline ingredient as shown by Ayyanagar (see examples 1-6).

8. Claims 15-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Phillips (Chemist Druggist, cited on applicants form 1449).

Phillips discloses a process for preparing codeine by methylation of morphine in an alkaline solution. Phillips differs from the instant claims that it does not mention using specific alkaline solution such as the instant alkaline metal phosphates. Therefore, in absence of an unexpected results of superior yield with the instant alkaline metal

Application/Control Number: 10/849,696 Page 4

Art Unit: 1625

phosphates, it would have been obvious to one skilled in the art to use any alkaline solution in the process of Phillip since the yield of codeine is obtained up to 95% by using alkaline solution as shown by Phillips.

Double Patenting

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

- 10. Claims 1-14 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-16 of copending Application No. 10/850,015. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the instant application using alkaline ingredients encompass the specific alkaline ingredients claimed in the cited application. This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is

Application/Control Number: 10/849,696

Art Unit: 1625

(571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571)272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

> C.S. fulaxl Charanjit S. Aulakh Primary Examiner

Art Unit 1625